Journal of Clinical Oncology, Vol 23, No 24 (August 20), 2005: pp. 5779-5787
© 2005 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.06.478
Immunomonitoring Tumor-Specific T Cells in Delayed-Type Hypersensitivity Skin Biopsies After Dendritic Cell Vaccination Correlates With Clinical Outcome
I. Jolanda M. de Vries,
Monique R. Bernsen,
W. Joost Lesterhuis,
Nicole M. Scharenborg,
Simon P. Strijk,
Marie-Jeanne P. Gerritsen,
Dirk J. Ruiter,
Carl G. Figdor,
Cornelis J.A. Punt,
Gosse J. Adema
From the Departments of Tumor Immunology, Medical Oncology, Pathology, Radiology, and Dermatology, Radbond University Nijmegen Medical Centre and Nijmegen Centre for Molecular Life Sciences, Nijmegen, the Netherlands
Address reprint requests to Gosse J. Adema, PhD, Department of Tumor Immunology, University Medical Center Nijmegen, Geert Grooteplein 26-28, 6500 HB Nijmegen, the Netherlands; e-mail: g.adema{at}ncmls.ru.nl
PURPOSE: Tumor-specific immunomonitoring is essential to evaluate the efficacy of vaccination against cancer. In this study, we investigated the predictive value of the presence or absence of antigen-specific T cells in biopsies from delayed-type hypersensitivity (DTH) sites.
PATIENTS AND METHODS: In our ongoing clinical trials, HLA-A2.1+ melanoma patients were vaccinated with mature dendritic cells (DC) pulsed with melanoma-associated peptides (gp100 and tyrosinase) and keyhole limpet hemocyanin.
RESULTS: After intradermal administration of a DTH challenge with gp100- and tyrosinase peptide-loaded DC, essentially all patients showed a positive induration. In clinically responding patients, T cells specific for the antigen preferentially accumulated in the DTH site, as visualized by in situ tetramer staining. Furthermore, significant numbers of functional gp100 and tyrosinase tetramer-positive T cells could be isolated from these DTH biopsies, in accordance with the applied antigen in the DTH challenge. We observed a direct correlation between the presence of DC vaccine-related T cells in the DTH biopsies of stage IV melanoma patients and a positive clinical outcome (P = .0012).
CONCLUSION: These findings demonstrate the potency of this novel approach in the monitoring of vaccination studies in cancer patients.
C.J.A.P and G.J.A. contributed equally to this study.
Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. Lotem, A. Machlenkin, T. Hamburger, A. Nissan, L. Kadouri, S. Frankenburg, Z. Gimmon, O. Elias, I. B. David, A. Kuznetz, et al.
Autologous Melanoma Vaccine Induces Antitumor and Self-Reactive Immune Responses That Affect Patient Survival and Depend on MHC Class II Expression on Vaccine Cells
Clin. Cancer Res.,
August 1, 2009;
15(15):
4968 - 4977.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. H. Schuurhuis, P. Verdijk, G. Schreibelt, E. H.J.G. Aarntzen, N. Scharenborg, A. de Boer, M. W.M.M. van de Rakt, M. Kerkhoff, M.-J. P. Gerritsen, F. Eijckeler, et al.
In situ Expression of Tumor Antigens by Messenger RNA-Electroporated Dendritic Cells in Lymph Nodes of Melanoma Patients
Cancer Res.,
April 1, 2009;
69(7):
2927 - 2934.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Verdijk, E. H.J.G. Aarntzen, W. J. Lesterhuis, A.C. I. Boullart, E. Kok, M. M. van Rossum, S. Strijk, F. Eijckeler, J. J. Bonenkamp, J. F.M. Jacobs, et al.
Limited Amounts of Dendritic Cells Migrate into the T-Cell Area of Lymph Nodes but Have High Immune Activating Potential in Melanoma Patients
Clin. Cancer Res.,
April 1, 2009;
15(7):
2531 - 2540.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Fontana, M. Bregni, A. Cipponi, L. Raccosta, C. Rainelli, D. Maggioni, F. Lunghi, F. Ciceri, S. Mukenge, C. Doglioni, et al.
Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients
Blood,
February 19, 2009;
113(8):
1651 - 1660.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Itoh, A. Yamada, T. Mine, and M. Noguchi
Recent Advances in Cancer Vaccines: An Overview
Jpn. J. Clin. Oncol.,
February 1, 2009;
39(2):
73 - 80.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Fong and E. J. Small
Anti-Cytotoxic T-Lymphocyte Antigen-4 Antibody: The First in an Emerging Class of Immunomodulatory Antibodies for Cancer Treatment
J. Clin. Oncol.,
November 10, 2008;
26(32):
5275 - 5283.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Xiong, S. Gharagozlou, I. Vengco, W. Chen, and J. R. Ohlfest
Effective CpG Immunotherapy of Breast Carcinoma Prevents but Fails to Eradicate Established Brain Metastasis
Clin. Cancer Res.,
September 1, 2008;
14(17):
5484 - 5493.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Thurnher
Lipids in dendritic cell biology: messengers, effectors, and antigens
J. Leukoc. Biol.,
January 1, 2007;
81(1):
154 - 160.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Schott
Immunesurveillance by dendritic cells: potential implication for immunotherapy of endocrine cancers.
Endocr. Relat. Cancer,
September 1, 2006;
13(3):
779 - 795.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. J. Lesterhuis, I. J. M. de Vries, D. H. Schuurhuis, A. C. I. Boullart, J. F. M. Jacobs, A. J. de Boer, N. M. Scharenborg, H. M. H. Brouwer, M. W. M. M. van de Rakt, C. G. Figdor, et al.
Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests
Ann. Onc.,
June 1, 2006;
17(6):
974 - 980.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|